154355-76-7

154355-76-7 structure

Name: Atreleuton
Chemical Name: 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
CAS Number: 154355-76-7
Molecular Formula: C₁₆H₁₅FN₂O₂S
Molecular Weight: 318.36600
Catalog: Signaling Pathways Metabolic Enzyme/Protease 5-Lipoxygenase
Create Date: 2017-12-06 10:38:31
Modify Date: 2024-01-02 12:26:04
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3].

Name	1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
Synonyms	[14C]-Atreleuton (R)-N-(3-(5-(4-fluorophenylmethyl)-2-thienyl)-1-methyl-2-propynyl)-N-hydroxyurea Atreleuton [USAN] Atreleuton ABT-761 Atreleuton (USAN/INN) UNII-U301T88E1M (R)-N-{3-[5-(4-fluorophenylmethyl)-thien-2-yl]-1-methyl-2-propynyl}-N-hydroxyurea

Description	Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> 5-Lipoxygenase
Target	5-LO[1]
References	[1]. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc. [2]. Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. [3]. Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73.

Density	1.37g/cm3
Boiling Point	506.7ºC at 760mmHg
Molecular Formula	C₁₆H₁₅FN₂O₂S
Molecular Weight	318.36600
Flash Point	260.2ºC
Exact Mass	318.08400
PSA	95.79000
LogP	3.50170
Vapour Pressure	4.34E-11mmHg at 25°C
Index of Refraction	1.652

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Hazard Codes	Xi
RIDADR	NONH for all modes of transport

154355-88-1

154355-92-7

~17%

154355-76-7

Literature: Brooks; Stewart; Basha; Bhatia; Ratajczyk; Martin; Craig; Kolasa; Bouska; Lanni; Harris; Malo; Carter; Bell Journal of Medicinal Chemistry, 1995 , vol. 38, # 24 p. 4768 - 4775

459-46-1

154355-76-7

Literature: Brooks; Stewart; Basha; Bhatia; Ratajczyk; Martin; Craig; Kolasa; Bouska; Lanni; Harris; Malo; Carter; Bell Journal of Medicinal Chemistry, 1995 , vol. 38, # 24 p. 4768 - 4775

63877-96-3

154355-76-7

Literature: Brooks; Stewart; Basha; Bhatia; Ratajczyk; Martin; Craig; Kolasa; Bouska; Lanni; Harris; Malo; Carter; Bell Journal of Medicinal Chemistry, 1995 , vol. 38, # 24 p. 4768 - 4775

154355-76-7	154355-75-6
1158522-08-7	2223856-03-7
940364-43-2	134104-43-1
131615-57-1	6906-52-1
930439-75-1	2310082-73-4
1018584-77-4	1703895-64-0